Our pipeline

We are currently running a Phase II trial in acute COVID-19. Clinical supplies have been manufactured and we are seeking partners to help accelerate the development and distribution of our products to ensure broad access as soon as possible.

Pre-clinical

Phase 1

Phase 2

Phase 3

Authorized

Acute COVID-19

We are currently investigating the use of ‘005 added to standard of care in hospitalized COVID-19 patients. Endpoints include WHO ranked improvements, 28-day discharge rates, and reduction in inflammatory markers.

Long-COVID

We have completed our initial human safety study and are preparing for Phase II studies.

Leishmaniasis

We have tested ‘005 in mice and showed positive results. Endpoints included prevention of lesions and improvement in clinical score.

Dengue

We are currently running proof-of-concept in-vivo studies in mice with our US-based research collaborators. Initial mouse studies show we are able to increase lifespans in AG129 mice.

Zika

We are preparing for in-vivo studies.

HCoV-OC43

We have demonstrated efficacy in-vitro.

HIV

We are exploring '005's effect in murine models of HIV